NCNA Key Statistics, Chart & Performance
The current stock price of NCNA is 4 USD. In the past month the price decreased by -0.25%. In the past year, price decreased by -99.99%.
NCNA Latest News, Press Relases and Analysis
NCNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About NCNA
Company Profile
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT GB
CEO: Hugh Griffith
Employees: 21
Phone: 4401313571111
NUCANA PLC-ADR / NCNA FAQ
What does NUCANA PLC-ADR do?
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Can you provide the latest stock price for NUCANA PLC-ADR?
The current stock price of NCNA is 4 USD. The price decreased by -6.54% in the last trading session.
What is the dividend status of NUCANA PLC-ADR?
NCNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NCNA stock?
NCNA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of NCNA stock?
NUCANA PLC-ADR (NCNA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for NCNA stock?
NUCANA PLC-ADR (NCNA) currently has 21 employees.
NCNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NCNA. When comparing the yearly performance of all stocks, NCNA is a bad performer in the overall market: 89.58% of all stocks are doing better.
NCNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NCNA. NCNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NCNA Financial Highlights
Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -286.47. The EPS increased by 98.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -195.78% | ||
| ROE | -430% | ||
| Debt/Equity | 0.01 |